5
01/02/2023
31/01/2024
2024-01-31
false
false
false
false
false
false
false
true
false
false
true
false
false
false
false
false
false
false
No description of principal activities is disclosed
2023-02-01
Sage Accounts Production 23.0 - FRS102_2023
xbrli:pure
xbrli:shares
iso4217:GBP
06157479
2023-02-01
2024-01-31
06157479
2024-01-31
06157479
2023-01-31
06157479
2022-02-01
2023-01-31
06157479
2023-01-31
06157479
2022-01-31
06157479
core:NetGoodwill
2023-02-01
2024-01-31
06157479
core:FurnitureFittingsToolsEquipment
2023-02-01
2024-01-31
06157479
core:MotorVehicles
2023-02-01
2024-01-31
06157479
bus:RegisteredOffice
2023-02-01
2024-01-31
06157479
bus:LeadAgentIfApplicable
2023-02-01
2024-01-31
06157479
bus:Director1
2023-02-01
2024-01-31
06157479
bus:CompanySecretary1
2023-02-01
2024-01-31
06157479
core:WithinOneYear
2024-01-31
06157479
core:WithinOneYear
2023-01-31
06157479
core:AfterOneYear
2024-01-31
06157479
core:AfterOneYear
2023-01-31
06157479
core:ShareCapital
2024-01-31
06157479
core:ShareCapital
2023-01-31
06157479
core:RetainedEarningsAccumulatedLosses
2024-01-31
06157479
core:RetainedEarningsAccumulatedLosses
2023-01-31
06157479
bus:Director1
2023-01-31
06157479
bus:Director1
2024-01-31
06157479
bus:Director1
2022-01-31
06157479
bus:Director1
2023-01-31
06157479
bus:Director1
2022-02-01
2023-01-31
06157479
bus:SmallEntities
2023-02-01
2024-01-31
06157479
bus:AuditExemptWithAccountantsReport
2023-02-01
2024-01-31
06157479
bus:SmallCompaniesRegimeForAccounts
2023-02-01
2024-01-31
06157479
bus:PrivateLimitedCompanyLtd
2023-02-01
2024-01-31
06157479
bus:AbridgedAccounts
2023-02-01
2024-01-31
Company registration number:
06157479
J.T.Smith & Son Pharma Limited
Unaudited filleted abridged financial statements
31 January 2024
J.T.Smith & Son Pharma Limited
Contents
Directors and other information
Accountants report
Abridged statement of financial position
Notes to the financial statements
J.T.Smith & Son Pharma Limited
Directors and other information
|
|
|
|
Director |
Mr Bharat Mistry |
|
|
|
|
|
|
|
Secretary |
Mrs Hemlata Mistry |
|
|
|
|
|
|
|
Company number |
06157479 |
|
|
|
|
|
|
|
Registered office |
6th Floor, AMP House |
|
|
Dingwall Road |
|
|
Croydon |
|
|
CR0 2LX |
|
|
|
|
|
|
|
Accountants |
Doshi & Co. Accountants |
|
|
6th Floor, AMP House |
|
|
Dingwall Road |
|
|
Croydon |
|
|
CR0 2LX |
|
|
|
J.T.Smith & Son Pharma Limited
Report to the director on the preparation of the
unaudited statutory financial statements of J.T.Smith & Son Pharma Limited
Year ended 31 January 2024
As described on the statement of financial position, the director of the company is responsible for the preparation of the financial statements for the year ended 31 January 2024 which comprise the abridged statement of financial position and related notes.
You consider that the company is exempt from an audit under the Companies Act 2006. In accordance with your instructions we have compiled these unaudited financial statements in order to assist you to fulfil your statutory responsibilities, from the accounting records and from information and explanations supplied to us.
Doshi & Co. Accountants
6th Floor, AMP House
Dingwall Road
Croydon
CR0 2LX
26 October 2024
J.T.Smith & Son Pharma Limited
Abridged statement of financial position
31 January 2024
|
|
|
2024 |
|
|
|
2023 |
|
|
|
|
Note |
£ |
|
£ |
|
£ |
|
£ |
|
|
|
|
|
|
|
|
|
|
Fixed assets |
|
|
|
|
|
|
|
|
|
Intangible assets |
|
5 |
110,364 |
|
|
|
137,957 |
|
|
Tangible assets |
|
6 |
1,665 |
|
|
|
2,768 |
|
|
|
|
|
_______ |
|
|
|
_______ |
|
|
|
|
|
|
|
112,029 |
|
|
|
140,725 |
|
|
|
|
|
|
|
|
|
|
Current assets |
|
|
|
|
|
|
|
|
|
Stocks |
|
|
83,213 |
|
|
|
74,936 |
|
|
Debtors |
|
|
96,629 |
|
|
|
83,164 |
|
|
Cash at bank and in hand |
|
|
1,085,693 |
|
|
|
1,000,117 |
|
|
|
|
|
_______ |
|
|
|
_______ |
|
|
|
|
|
1,265,535 |
|
|
|
1,158,217 |
|
|
Creditors: amounts falling due |
|
|
|
|
|
|
|
|
|
within one year |
|
|
(
695,096) |
|
|
|
(
685,519) |
|
|
|
|
|
_______ |
|
|
|
_______ |
|
|
Net current assets |
|
|
|
|
570,439 |
|
|
|
472,698 |
|
|
|
|
|
_______ |
|
|
|
_______ |
Total assets less current liabilities |
|
|
|
|
682,468 |
|
|
|
613,423 |
|
|
|
|
|
|
|
|
|
|
Creditors: amounts falling due |
|
|
|
|
|
|
|
|
|
after more than one year |
|
7 |
|
|
(
220,000) |
|
|
|
(
220,000) |
|
|
|
|
|
_______ |
|
|
|
_______ |
Net assets |
|
|
|
|
462,468 |
|
|
|
393,423 |
|
|
|
|
|
_______ |
|
|
|
_______ |
|
|
|
|
|
|
|
|
|
|
Capital and reserves |
|
|
|
|
|
|
|
|
|
Called up share capital |
|
|
|
|
4 |
|
|
|
4 |
Profit and loss account |
|
|
|
|
462,464 |
|
|
|
393,419 |
|
|
|
|
|
_______ |
|
|
|
_______ |
Shareholders funds |
|
|
|
|
462,468 |
|
|
|
393,423 |
|
|
|
|
|
_______ |
|
|
|
_______ |
|
|
|
|
|
|
|
|
|
|
For the year ending 31 January 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
Director's responsibilities:
-
The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476;
-
The director acknowledges their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements.
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with Section 1A of FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.
In accordance with section 444 of the Companies Act 2006, the abridged statement of comprehensive income has not been delivered.
All of the members have consented to the preparation of the abridged statement of comprehensive income and the abridged statement of financial position for the current year ending 31 January 2024 in accordance with Section 444(2A) of the Companies Act 2006.
These financial statements were approved by the
board of directors
and authorised for issue on
26 October 2024
, and are signed on behalf of the board by:
X
Mr Bharat Mistry
Director
Company registration number:
06157479
J.T.Smith & Son Pharma Limited
Notes to the financial statements
Year ended 31 January 2024
1.
General information
The company is a private company limited by shares, registered in England and Wales. The address of the registered office is 6th Floor, AMP House, Dingwall Road, Croydon, CR0 2LX.
2.
Statement of compliance
These financial statements have been prepared in compliance with the provisions of FRS 102, Section 1A, 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.
3.
Accounting policies
Basis of preparation
The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.
The financial statements are prepared in sterling, which is the functional currency of the entity.
Turnover
Turnover is measured at the fair value of the consideration received or receivable for goods supplied and services rendered, net of discounts and Value Added Tax.
Revenue from the sale of goods is recognised when the significant risks and rewards of ownership have transferred to the buyer (usually on despatch of the goods); the amount of revenue can be measured reliably; it is probable that the associated economic benefits will flow to the entity; and the costs incurred or to be incurred in respect of the transactions can be measured reliably.
Exceptional items
Exceptional items are disclosed separately in the financial statements in order to provide further understanding of the financial performance of the entity. They are material items of income or expense that have been shown separately because of their nature or amount.
Taxation
The taxation expense represents the aggregate amount of current and deferred tax recognised in the reporting period. Tax is recognised in the statement of comprehensive income, except to the extent that it relates to items recognised in other comprehensive income or directly in capital and reserves. In this case, tax is recognised in other comprehensive income or directly in capital and reserves, respectively. Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.
Deferred tax is recognised in respect of all timing differences at the reporting date. Unrelieved tax losses and other deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date that are expected to apply to the reversal of the timing difference.
Operating leases
Goodwill
Goodwill arises on business acquisitions and represents the excess of the cost of the acquisition over the company's interest in the net amount of the identifiable assets, liabilities and contingent liabilities of the acquired business. Goodwill is measured at cost less accumulated amortisation and accumulated impairment losses. It is amortised on a straight line basis over its useful life. Where a reliable estimate of the useful life of goodwill or intangible assets cannot be made, the life is presumed not to exceed ten years.
Intangible assets
Intangible assets are initially recorded at cost, and are subsequently stated at cost less any accumulated amortisation and impairment losses. Any intangible assets carried at a revalued amount, are recorded at the fair value at the date of revaluation, as determined by reference to an active market, less any subsequent accumulated amortisation and subsequent accumulated impairment losses. Intangible assets acquired as part of a business combination are only recognised separately from goodwill when they arise from contractual or other legal rights, are separable, the expected future economic benefits are probable and the cost or value can be measured reliably.
Amortisation
Amortisation is calculated so as to write off the cost of an asset, less its estimated residual value, over the useful life of that asset as follows:
|
|
|
|
Goodwill |
- |
5 % |
straight line |
|
|
|
|
If there is an indication that there has been a significant change in amortisation rate, useful life or residual value of an intangible asset, the amortisation is revised prospectively to reflect the new estimates.
Tangible assets
tangible assets are initially recorded at cost, and are subsequently stated at cost less any accumulated depreciation and impairment losses. Any tangible assets carried at revalued amounts are recorded at the fair value at the date of revaluation less any subsequent accumulated depreciation and subsequent accumulated impairment losses. An increase in the carrying amount of an asset as a result of a revaluation, is recognised in other comprehensive income and accumulated in capital and reserves, except to the extent it reverses a revaluation decrease of the same asset previously recognised in profit or loss. A decrease in the carrying amount of an asset as a result of revaluation is recognised in other comprehensive income to the extent of any previously recognised revaluation increase accumulated in capital and reserves in respect of that asset. Where a revaluation decrease exceeds the accumulated revaluation gains accumulated in capital and reserves in respect of that asset, the excess shall be recognised in profit or loss.
Depreciation
Depreciation is calculated so as to write off the cost or valuation of an asset, less its residual value, over the useful economic life of that asset as follows:
|
|
|
|
|
|
Fittings fixtures and equipment |
- |
25 % |
reducing balance |
|
Motor vehicles |
- |
25 % |
reducing balance |
|
|
|
|
|
If there is an indication that there has been a significant change in depreciation rate, useful life or residual value of tangible assets, the depreciation is revised prospectively to reflect the new estimates.
Impairment
A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible reversal at each reporting date. When it is not possible to estimate the recoverable amount of an individual asset, an estimate is made of the recoverable amount of the cash-generating unit to which the asset belongs. The cash-generating unit is the smallest identifiable group of assets that includes the asset and generates cash inflows that are largely independent of the cash inflows from other assets or groups of assets. For impairment testing of goodwill, the goodwill acquired in a business combination is, from the acquisition date, allocated to each of the cash-generating units that are expected to benefit from the synergies of the combination, irrespective of whether other assets or liabilities of the company are assigned to those units.
Stocks
Stocks are measured at the lower of cost and estimated selling price less costs to complete and sell. Cost includes all costs of purchase, costs of conversion and other costs incurred in bringing the stocks to their present location and condition.
Financial instruments
A financial asset or a financial liability is recognised only when the company becomes a party to the contractual provisions of the instrument. Basic financial instruments are initially recognised at the transaction price, unless the arrangement constitutes a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Debt instruments are subsequently measured at amortised cost. Where investments in non-convertible preference shares and non-puttable ordinary shares or preference shares are publicly traded or their fair value can otherwise be measured reliably, the investment is subsequently measured at fair value with changes in fair value recognised in profit or loss. All other such investments are subsequently measured at cost less impairment. Other financial instruments, including derivatives, are initially recognised at fair value, unless payment for an asset is deferred beyond normal business terms or financed at a rate of interest that is not a market rate, in which case the asset is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Other financial instruments are subsequently measured at fair value, with any changes recognised in profit or loss, with the exception of hedging instruments in a designated hedging relationship.
Financial assets that are measured at cost or amortised cost are reviewed for objective evidence of impairment at the end of each reporting date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss immediately. For all equity instruments regardless of significance, and other financial assets that are individually significant, these are assessed individually for impairment. Other financial assets or either assessed individually or grouped on the basis of similar credit risk characteristics. Any reversals of impairment are recognised in profit or loss immediately, to the extent that the reversal does not result in a carrying amount of the financial asset that exceeds what the carrying amount would have been had the impairment not previously been recognised.
Defined contribution plans
Contributions to defined contribution plans are recognised as an expense in the period in which the related service is provided. Prepaid contributions are recognised as an asset to the extent that the prepayment will lead to a reduction in future payments or a cash refund. When contributions are not expected to be settled wholly within 12 months of the end of the reporting date in which the employees render the related service, the liability is measured on a discounted present value basis. The unwinding of the discount is recognised in finance costs in profit or loss in the period in which it arises.
4.
Employee numbers
The average number of persons employed by the company during the year amounted to
5
(2023:
5
).
5.
Intangible assets
|
|
|
|
|
|
|
|
|
|
£ |
|
|
|
|
|
|
Cost |
|
|
|
|
|
|
|
At 1 February 2023 and 31 January 2024 |
551,850 |
|
|
|
|
|
|
|
_______ |
|
|
|
|
|
|
Amortisation |
|
|
|
|
|
|
|
At 1 February 2023 |
413,893 |
|
|
|
|
|
|
Charge for the year |
27,593 |
|
|
|
|
|
|
|
_______ |
|
|
|
|
|
|
At 31 January 2024 |
441,486 |
|
|
|
|
|
|
|
_______ |
|
|
|
|
|
|
Carrying amount |
|
|
|
|
|
|
|
At 31 January 2024 |
110,364 |
|
|
|
|
|
|
|
_______ |
|
|
|
|
|
|
At 31 January 2023 |
137,957 |
|
|
|
|
|
|
|
_______ |
|
|
|
|
|
|
|
|
|
|
|
|
|
6.
Tangible assets
|
|
|
|
|
|
|
|
|
|
|
£ |
|
|
|
|
|
|
|
Cost |
|
|
|
|
|
|
|
|
At 1 February 2023 |
30,164 |
|
|
|
|
|
|
|
Additions |
374 |
|
|
|
|
|
|
|
Disposals |
(
9,215) |
|
|
|
|
|
|
|
|
_______ |
|
|
|
|
|
|
|
At 31 January 2024 |
21,323 |
|
|
|
|
|
|
|
|
_______ |
|
|
|
|
|
|
|
Depreciation |
|
|
|
|
|
|
|
|
At 1 February 2023 |
27,396 |
|
|
|
|
|
|
|
Charge for the year |
786 |
|
|
|
|
|
|
|
Disposals |
(
8,524) |
|
|
|
|
|
|
|
|
_______ |
|
|
|
|
|
|
|
At 31 January 2024 |
19,658 |
|
|
|
|
|
|
|
|
_______ |
|
|
|
|
|
|
|
Carrying amount |
|
|
|
|
|
|
|
|
At 31 January 2024 |
1,665 |
|
|
|
|
|
|
|
|
_______ |
|
|
|
|
|
|
|
At 31 January 2023 |
2,768 |
|
|
|
|
|
|
|
|
_______ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
7.
Creditors: amounts falling due after more than one year
To ensure that the company will remain in a position to meet all external liabilities the director has agreed to postpone drawing against £220,000 (2023 : £220,000) of his directors current account for at least one year.
8.
Directors advances, credits and guarantees
|
During the year the director entered into the following advances and credits with the company: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2024 |
|
|
|
|
|
|
|
|
|
Balance brought forward |
Advances /(credits) to the director |
Balance o/standing |
|
|
|
|
|
£ |
£ |
£ |
|
|
|
|
Mr Bharat Mistry |
(
397,575) |
25,165 |
(
372,410) |
|
|
|
|
|
_______ |
_______ |
_______ |
|
|
|
|
|
|
|
|
|
|
|
2023 |
|
|
|
|
|
|
|
|
|
Balance brought forward |
Advances /(credits) to the director |
Balance o/standing |
|
|
|
|
|
£ |
£ |
£ |
|
|
|
|
Mr Bharat Mistry |
(
408,770) |
11,195 |
(
397,575) |
|
|
|
|
|
_______ |
_______ |
_______ |
|
|
|
|
|
|
|
|
|
|
|
9.
Related party transactions
Lease of business premises
-
-
The director has leased the personally owned business premises to the company at a nominal rent of £1 per annum. The company agrees to pay all business rates and utility bills and to keep the premises insured and in a fit state of repair.
10.
Controlling party
The company is controlled by the director who owns 50% of the called up share capital.A family member owns the remaining 50% of the called up share capital.